Vanguard Capital Management
IMRX icon

Vanguard Capital Management’s Immuneering IMRX Stock Holding History

Vanguard Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Sell
2,286,434
-1,907
-0.1% -$9.65K ﹤0.01% 2738
2026
Q1 		$12.1M Buy
+2,288,341
New +$11.7M ﹤0.01% 2627

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Vanguard Capital Management's IMRX Position: Q2 2026 in Review

Vanguard Capital Management reduced its Immuneering (IMRX) stake by 0.08% in Q2 2026, selling an estimated $9.65K and leaving 2,286,434 shares worth $11.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2738.

Vanguard Capital Management first reported a position in IMRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $12.1M in Q1 2026. 110 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Vanguard Capital Management held 2,286,434 shares of Immuneering worth $11.4M as of Q2 2026.
  • Vanguard Capital Management sold 1,907 Immuneering shares in Q2 2026, an estimated $9.65K.
  • Immuneering made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2738 holding.
  • Vanguard Capital Management first reported a position in Immuneering in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Immuneering position peaked at $12.1M in Q1 2026.
  • 110 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.